Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant type III humanized collagen facial injection: blunt versus sharp needle
ChiCTR2400082098Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-blind trial of recombinant type III humanized collagen solution in rhytides and photoaging (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Improvement rate in Lemperle wrinkle grade assessed by blinded investigator. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
recombinant type III humanized collagen solution
03
Conditions
rhytidesphotoaging
Beyond the preview
Go deeper on ChiCTR2400082098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082098.